Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasAddiction psychiatry

Psych Vivas · Addiction psychiatry

Benzodiazepine dependence — structured clinical viva

Fellowship viva on BZD/Z-drug dependence in older adults, deprescribing, taper safety, and interaction hazards.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A GP rings about a 70-year-old woman on nitrazepam 10 mg nightly for 12 years plus recent zopiclone 7.5 mg. Two falls, Mini-Cog decline, daughter wants everything stopped tomorrow. Junior doctor suggests flumazenil 'detox', lifelong zolpidem only, or abrupt stop with 'supportive vitamins'. Cross-examine on elderly harm, Z-drugs, taper, EMPOWER/deprescribing evidence, withdrawal seizures, and alcohol/opioid interaction counselling.

Interpretation

Reveal interpretation

Reject the junior plan. Abrupt stop after 12 years risks severe withdrawal including seizures. Flumazenil is not community detox. Zolpidem/zopiclone are not safe long-term elderly substitutes — they act at related GABA-A sites and carry falls/cognition risk. Vitamins alone are not a taper.[3][1][6]

Elderly harm frame. Falls, fractures, cognitive adverse events, delirium risk; Glass meta-analysis shows modest sleep benefit versus harm; Markota review summarises dangers and alternatives.[1][2]

Plan. Shared deprescribing: education (EMPOWER logic), Canadian BRZA-style conversation, convert/combine to a single taperable regimen, gradual reductions, CBT-I/sleep hygiene, review polypharmacy, involve daughter as support not as enforcer of cold turkey, monitor mobility and cognition.[4][5][7][3]

Interactions. Counsel against alcohol and future opioid co-use because of synergistic depression.[6]

Escalating viva probes

  1. Why might short-acting agents produce earlier withdrawal than diazepam?
  2. Name risks of flumazenil in chronic users.
  3. What did EMPOWER actually randomise?
  4. How do you distinguish protracted withdrawal from primary GAD relapse?
  5. When is inpatient taper preferred?
[3] [4] [6] [7]

Key points

Z-drugs

Not non-addictive elderly sleeping solutions.

After seizure

Reinstate cover, then taper — never moral cold turkey alone.

EMPOWER

Patient education can reduce inappropriate BZD use.
[1] [3] [4]

References

  1. [1]Markota M, Rummans TA, Bostwick JM, et al. Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies Mayo Clin Proc, 2016.PMID 27814838
  2. [2]Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208
  3. [3]Brett J, Murnion B. Management of benzodiazepine misuse and dependence Aust Prescr, 2015.PMID 26648651
  4. [4]Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial JAMA Intern Med, 2014.PMID 24733354
  5. [5]Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline Can Fam Physician, 2018.PMID 29760253
  6. [6]Soyka M. Treatment of Benzodiazepine Dependence N Engl J Med, 2017.PMID 28614686
  7. [7]Brunner E, Chen CA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits J Gen Intern Med, 2025.PMID 40526204